Miniatura

Fitxers

859095.pdf (2.79 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-01-10

Llicència de publicació

cc-by (c) García Corbacho et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/214349

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1007/s00262-022-03360-9

Resum

Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need. One-hundred-forty-six patients with metastatic cancer candidates to ICI at the Hospital Clinic of Barcelona Clinical Trials Unit were prospectively recruited in this observational study. Blood samples were collected at different timepoints, baseline LIPI score calculated and pre-ICI archived tissues retrieved to evaluate PD-L1, tumor-infiltrating lymphocytes (TILs) and PD1 mRNA levels. Tumor assessments were centrally reviewed by RECIST 1.1 criteria. Associations with overall response rates (ORR), durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) were performed with univariable/multivariable logistic and Cox regressions, where appropriate. At a median follow-up of 26.9 months, median PFS and OS were 2.7 and 12.9 months. Response rates were 17.8% with duration of response (DOR) of 4.4 months. LIPI score was independently associated with PFS (p = 0.025) and OS (p < 0.001). Immunotherapy-naïve status was independently associated with better PFS (p = 0.005). Time-to-best response (TTBR) and ORR (p < 0.001 both) were associated with better OS at univariate analysis. PFS and DOR were moderately correlated with OS (p < 0.001 both). A PD-L1 10% cut-off detected worse/best responders in terms of ORR (univariate p = 0.011, multivariate p = 0.028) and DCB (univariate p = 0.043). PD1 mRNA levels were strikingly associated to complete responses (p = 0.021). To resume, in our prospective observational pan-cancer study, baseline LIPI score, immunotherapy-naïve status, cancer type and RT before starting ICI were the most relevant clinical factors independently correlated with immunotherapy outcomes. Longer TTBR seemed to associate with better survival, while PD1 mRNA and PD-L1 protein levels might be tumor-agnostic predictive factors of response to ICI and should be furtherly explored.

Matèries

Immunoteràpia, Tumors, Marcadors bioquímics, Medicaments antineoplàstics

Matèries (anglès)

Immunotheraphy, Tumors, Biochemical markers, Antineoplastic agents

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

GARCÍA CORBACHO, Javier, INDACOCHEA, Alberto, GONZÁLEZ NAVARRO, Azucena e., VICTORIA, Iván, MORENO, Debora, PESANTEZ, David, ANGELATS, Laura, MODREGO SANCHEZ, Andrea, SANFELIU, Esther, CASTILLO, Oleguer, BLASCO, Paula, MEZQUITA, Laura, VIÑOLAS SEGARRA, Núria, NOGUÉ, Miquel, GALVÁN, Patricia, ADAMO, Barbara, BASTÉ, Neus, SAURÍ, Tamara, Juan Manel, PRAT APARICIO, Aleix, SCHETTINI, Francesco. Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study. _Cancer Immunology Immunotherapy_. 2023. Vol. 72, núm. 6, pàgs. 1709-1723. [consulta: 25 de gener de 2026]. ISSN: 0340-7004. [Disponible a: https://hdl.handle.net/2445/214349]

Exportar metadades

JSON - METS

Compartir registre